We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+1.66%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.45B
AUM Growth
+$98.6M
Cap. Flow
+$39.6M
Cap. Flow %
1.62%
Top 10 Hldgs %
39.51%
Holding
166
New
25
Increased
26
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$38M
2
COR icon
Cencora
COR
+$30.2M
3
CVS icon
CVS Health
CVS
+$22.3M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$21M
5
GILD icon
Gilead Sciences
GILD
+$16M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$36M
2
MDVN
MEDIVATION, INC.
MDVN
+$23.3M
3
NVO
Novo Nordisk
NVO
+$16M
4
VTR icon
Ventas
VTR
+$14.3M
5
DOC
PHYSICIANS REALTY TRUST
DOC
+$13.4M

Sector Composition

Rank Sector Weight
1 Healthcare 86.46%
2 Real Estate 2.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVTX icon
76
Travere Therapeutics
TVTX
$5.33B
$5.88M 0.24%
329,949
– –
LTC
77
LTC Properties
LTC
$2.06B
$5.49M 0.22%
106,212
-130,406
-55% -$6.21M
ICLR icon
78
Icon
ICLR
$12.8B
$5.04M 0.21%
72,000
-42,900
-37% -$2.94M
DVAX
79
DELISTED
Dynavax Technologies
DVAX
$5.03M 0.21%
345,050
+104,100
+43% +$1.78M
NBIX icon
80
CALL
Neurocrine Biosciences
NBIX
$18.7B
$5.02M 0.2%
+110,400
New +$5.08M
ABT icon
81
CALL
Abbott
ABT
$183B
$4.87M 0.2%
+123,800
New +$4.93M
ALKS icon
82
CALL
Alkermes
ALKS
$8.39B
$4.84M 0.2%
+111,900
New +$4.62M
GILD icon
83
CALL
Gilead Sciences
GILD
$163B
$4.79M 0.2%
+57,400
New +$5.09M
THC icon
84
Tenet Healthcare
THC
$21.8B
$4.55M 0.19%
164,500
– –
VTRS icon
85
CALL
Viatris
VTRS
$20.7B
$4.52M 0.18%
+104,600
New +$4.63M
BMRN icon
86
CALL
BioMarin Pharmaceuticals
BMRN
$11.7B
$4.49M 0.18%
+57,700
New +$4.91M
ENDP
87
DELISTED
Endo International plc
ENDP
$4.46M 0.18%
286,348
– –
SAGE
88
DELISTED
Sage Therapeutics
SAGE
$4.42M 0.18%
146,800
– –
RARE icon
89
Ultragenyx Pharmaceutical
RARE
$2.56B
$4.32M 0.18%
88,400
– –
SGNT
90
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$4.29M 0.18%
286,650
– –
PRAH
91
DELISTED
PRA Health Sciences, Inc.
PRAH
$4.26M 0.17%
+102,000
New +$4.7M
AGN.PRA
92
DELISTED
Allergan plc
AGN.PRA
$4.17M 0.17%
5,000
– –
EPZM
93
DELISTED
Epizyme, Inc
EPZM
$4.1M 0.17%
400,000
– –
ASRT
94
DELISTED
Assertio
ASRT
$3.92M 0.16%
3,333
– –
BHC icon
95
Bausch Health
BHC
$2.25B
$3.87M 0.16%
192,000
+34,000
+22% +$963K
AXDX
96
DELISTED
Accelerate Diagnostics
AXDX
$3.81M 0.16%
26,463
– –
ARIA
97
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$3.71M 0.15%
+502,000
New +$3.77M
NVRO
98
DELISTED
NEVRO CORP.
NVRO
$3.67M 0.15%
49,800
– –
CYH icon
99
Community Health Systems
CYH
$391M
$3.67M 0.15%
304,472
-63,939
-17% -$937K
MDVN
100
CALL
DELISTED
MEDIVATION, INC.
MDVN
$3.62M 0.15%
+60,000
New +$3.4M
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, Tekla Capital Management held 166 positions worth $2.45B, up 4.2% from $2.35B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q2 2016 filing shows 25 new, 26 increased, 19 reduced and 10 closed positions. Its largest new stake was Abbott: 953,500 shares worth $37.5M. The largest sale was Celgene Corp, an estimated $36M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2016 buy was Abbott: 953,500 shares worth $37.5M.
  • Tekla Capital Management added most to Neurocrine Biosciences in Q2 2016, an estimated $21M increase.
  • Tekla Capital Management's biggest Q2 2016 reduction was Celgene Corp, cutting an estimated $36M.
  • Tekla Capital Management fully exited Novo Nordisk in Q2 2016, selling an estimated $16M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.45B portfolio in Q2 2016.
  • Tekla Capital Management opened 25 new positions and closed 10 in Q2 2016.
  • Tekla Capital Management's portfolio value rose 4.2% quarter-over-quarter to $2.45B.

Based on Tekla Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.